RBC Europe’s Neurocrine Biosciences NBIX Stock Holding History

RBC Europe’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-115	Closed	-$11K	–	947
2021 Q3	$11K	Hold	115	–	–	﹤0.01%	917
2021 Q2	$11.2K	Sell	115 -75	-39%	-$7.19K	﹤0.01%	931
2021 Q1	$18.5K	Hold	190	–	–	﹤0.01%	786
2020 Q4	$18.2K	Buy	190 +115	+153%	+$11.1K	﹤0.01%	743
2020 Q3	$7.21K	Hold	75	–	–	﹤0.01%	858
2020 Q2	$9.15K	Hold	75	–	–	﹤0.01%	785
2020 Q1	$6.49K	Hold	75	–	–	﹤0.01%	788
2019 Q4	$8.06K	Hold	75	–	–	﹤0.01%	837
2019 Q3	$6.76K	Hold	75	–	–	﹤0.01%	856
2019 Q2	$6.33K	Hold	75	–	–	﹤0.01%	884
2019 Q1	$6.61K	Hold	75	–	–	﹤0.01%	895
2018 Q4	$5.36K	Hold	75	–	–	﹤0.01%	915
2018 Q3	$9.22K	Hold	75	–	–	﹤0.01%	868
2018 Q2	$7.37K	Hold	75	–	–	﹤0.01%	907
2018 Q1	$6.22K	Buy	+75	New	+$6.33K	﹤0.01%	917

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RBC Europe's NBIX Position: Q4 2021 in Review

RBC Europe sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 115 shares — an estimated $11K sold.

RBC Europe first reported a position in NBIX in Q1 2018 and held it in 15 quarters. The position peaked at $18.5K in Q1 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

RBC Europe reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 115 Neurocrine Biosciences shares in Q4 2021, an estimated $11K.
RBC Europe first reported a position in Neurocrine Biosciences in Q1 2018 and held it in 15 quarters.
RBC Europe's Neurocrine Biosciences position peaked at $18.5K in Q1 2021.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.